Details of the Drug

General Information of Drug (ID: DMGK1JE)

Drug Name
MORAb-004
Indication
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Phase 2 [1]
Melanoma 2C30 Phase 2 [1]
Merkel cell carcinoma 2C34 Phase 2 [2]
Sarcoma 2A60-2C35 Phase 2 [1]
Cross-matching ID
TTD ID
D02RKG
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Endosialin (CD248) TTYJWT7 CD248_HUMAN Modulator [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01574716) Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation. (SOURCE). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors. Clin Cancer Res. 2015 Mar 15;21(6):1281-8.